Your browser doesn't support javascript.
loading
European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO.
Rubio, Isabel T; Wyld, Lynda; Marotti, Lorenza; Athanasiou, Alexandra; Regitnig, Peter; Catanuto, Giuseppe; Schoones, Jan W; Zambon, Marzia; Camps, Julia; Santini, Donatella; Dietz, Jill; Sardanelli, Francesco; Varga, Zsuzsanna; Smidt, Marjolein; Sharma, Nisha; Shaaban, Abeer M; Gilbert, Fiona.
Afiliação
  • Rubio IT; Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Spain; European Society of Breast Cancer Specialists (EUSOMA), Florence, Italy; European Society of Surgical Oncology (ESSO), Brussels, Belgium. Electronic address: irubior@unav.es.
  • Wyld L; Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK; Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK.
  • Marotti L; European Society of Breast Cancer Specialists (EUSOMA), Florence, Italy.
  • Athanasiou A; Breast Imaging Department, MITERA Hospital, Athens, UK.
  • Regitnig P; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Catanuto G; Humanitas-Istituto Clinico Catanese Misterbianco, Italy; Fondazione G.Re.T.A., ETS, Napoli, Italy.
  • Schoones JW; Research Policy & Graduate School Advisor, Leiden University Medical Center Leiden, the Netherlands.
  • Zambon M; Europa Donna - The European Breast Cancer Coalition, Milan, Italy.
  • Camps J; Breast Health Units in Ribera Salud Hospitals.Valencia, Spain.
  • Santini D; Department of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
  • Dietz J; The American Society of Breast Surgeons, Columbia, MD, USA.
  • Sardanelli F; Department of Biomedical Sciences for Health, Università Degli Studi di Milano, Milan, Italy; Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
  • Varga Z; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Smidt M; GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Sharma N; Breast Unit, Level 1 Chancellor Wing, St James Hospital, Beckett Street Leeds, West Yorkshire, LS9 7TF, UK.
  • Shaaban AM; Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Gilbert F; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, UK. Electronic address: fjg28@cam.ac.uk.
Eur J Surg Oncol ; 50(1): 107292, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38061151
ABSTRACT

INTRODUCTION:

Breast lesions of uncertain malignant potential (B3) include atypical ductal and lobular hyperplasias, lobular carcinoma in situ, flat epithelial atypia, papillary lesions, radial scars and fibroepithelial lesions as well as other rare miscellaneous lesions. They are challenging to categorise histologically, requiring specialist training and multidisciplinary input. They may coexist with in situ or invasive breast cancer (BC) and increase the risk of subsequent BC development. Management should focus on adequate classification and management whilst avoiding overtreatment. The aim of these guidelines is to provide updated information regarding the diagnosis and management of B3 lesions, according to updated literature review evidence.

METHODS:

These guidelines provide practical recommendations which can be applied in clinical practice which include recommendation grade and level of evidence. All sections were written according to an updated literature review and discussed at a consensus meeting. Critical appraisal by the expert writing committee adhered to the 23 items in the international Appraisal of Guidelines, Research and Evaluation (AGREE) tool.

RESULTS:

Recommendations for further management after core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB) diagnosis of a B3 lesion reported in this guideline, vary depending on the presence of atypia, size of lesion, sampling size, and patient preferences. After CNB or VAB, the option of vacuum-assisted excision or surgical excision should be evaluated by a multidisciplinary team and shared decision-making with the patient is crucial for personalizing further treatment. De-escalation of surgical intervention for B3 breast lesions is ongoing, and the inclusion of vacuum-assisted excision (VAE) will decrease the need for surgical intervention in further approaches. Communication with patients may be different according to histological diagnosis, presence or absence of atypia, or risk of upgrade due to discordant imaging. Written information resources to help patients understand these issues alongside with verbal communication is recommended. Lifestyle interventions have a significant impact on BC incidence so lifestyle interventions need to be suggested to women at increased BC risk as a result of a diagnosis of a B3 lesion.

CONCLUSIONS:

These guidelines provide a state-of-the-art overview of the diagnosis, management and prognosis of B3 lesions in modern multidisciplinary breast practice.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mama / Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Eur J Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mama / Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Eur J Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article